Semaglutide Significantly Cuts Heavy Drinking Days in Phase II Alcohol Study

A phase II randomized clinical trial found that semaglutide, a GLP-1 receptor agonist known from diabetes and obesity treatment, reduced heavy drinking and alcohol craving among adults with alcohol use disorder (AUD). The results suggest that semaglutide might fill a large treatment gap in managing AUD.

Introduction

Background and Context

Semaglutide is a long-acting GLP-1 receptor agonist, approved in the US for diabetes since 2017 and for obesity since 2021. Many patients report lower alcohol use while taking GLP-1 drugs, and preclinical studies showed these drugs can cut alcohol consumption in animals. Until now, there has been little trial evidence in people with AUD.

Alcohol use is a major preventable cause of illness and death, linked to about 178,000 US deaths per year. While almost a third of US adults meet criteria for AUD during their life, fewer than 10% are treated, and less than 2% get pharmacotherapy. This gap is due to a lack of approved drugs, low awareness, and stigma. GLP-1 drugs like semaglutide, which are already widely prescribed, might be useful for treating AUD.

What the Latest Research Says About Semaglutide and AUD?

In this trial, 48 adults with moderate AUD were recruited. They were not seeking treatment and were randomized to semaglutide or placebo injection for nine weeks. Only low semaglutide doses were used (0.25 mg/week to 0.5 mg/week) for safety. Drinking was measured both by self-report and lab-based self-administration sessions.

Key findings:

Semaglutide reduced the number of drinks per drinking day (β, −0.41; P = .04) and heavy drinking days over time compared to placebo.
There was a significant drop in alcohol craving.
The number of drinking days did not change, but more patients in the semaglutide group reported zero heavy drinking days at the end.
Effect sizes for these outcomes were large at 0.5 mg/week.
Semaglutide also led to an average weight loss of 5% over the study.
Side effects were mostly mild and as expected. There were no serious adverse events or problems mixing with alcohol.

The researchers note that reducing heavy drinking and cravings—as opposed to insisting on abstinence—may be more achievable for most people with AUD. “The broad uptake of GLP-1RAs presents an ideal scenario for medication repurposing, with potential to help reduce the wide treatment gap associated with AUD.”

Market Comparison

The only approved medications for AUD—disulfiram, naltrexone, and acamprosate—have had limited impact. In this study, effect sizes for semaglutide were larger than those seen in previous studies of these drugs. Notably, semaglutide was effective at low doses, suggesting potential for stronger effects at higher clinical doses used in obesity.

Future Perspectives

Larger and longer-term trials are needed to see if semaglutide helps patients who are actively trying to quit alcohol, and whether higher doses have greater impact without safety concerns. The findings suggest existing GLP-1 drugs might be quickly repurposed for AUD treatment, bypassing many of the barriers that have limited other medications.

Given that GLP-1 receptor agonists are already widely prescribed for metabolic diseases, exploring their use in AUD fits the growing industry trend of repurposing drugs for new indications. Addressing AUD with established therapies could rapidly increase pharmacotherapy rates and improve public health.